Controlled dangerous substances; authorizing divided quantities for certain acute pain opioid prescriptions. Effective date.
Impact
The proposed legislation is anticipated to have significant implications on state laws related to healthcare and drug control. By formalizing the regulations surrounding opioid prescriptions, SB1642 is expected to improve compliance among healthcare providers, ultimately leading to better patient outcomes. It also aims to enhance monitoring mechanisms, thereby reducing the risk of opioid abuse and dependence. With the growing epidemic of opioid addiction, this bill could establish new standards for responsible prescribing practices, which may influence how other states manage similar challenges.
Summary
SB1642 focuses on the regulation of controlled dangerous substances, specifically targeting opioid prescriptions for acute pain. The bill seeks to provide clarity and guidelines for prescribing opioids, allowing divided quantities for certain cases. This legislation aims to balance the need for effective pain management while addressing the growing concerns of opioid misuse and addiction. By delineating the circumstances under which prescriptions can be issued, SB1642 aims to create a more structured approach to opioid distribution in the state.
Sentiment
The general sentiment around SB1642 appears to be supportive among healthcare advocates and professionals who recognize the necessity of addressing pain management while also controlling substance misuse. However, there may be some apprehension regarding the enforcement aspects of the bill and its possible impact on physician autonomy in prescribing. Proponents view the legislation as a proactive step towards responsible opioid distribution, while critics may raise concerns about the rigidity of the proposed guidelines and their implications on patient care.
Contention
Debate around SB1642 may likely center on the effectiveness of the proposed regulations in mitigating opioid misuse while still ensuring patients have access to necessary pain relief. Some stakeholders could argue that the bill does not address underlying issues related to opioid addiction adequately or that it might impose unnecessary constraints on healthcare providers. These points of contention are expected to emerge during discussions as the bill moves through legislative processes, highlighting the ongoing challenges in developing comprehensive solutions to the opioid crisis.
Physicians assistants; Pharmacy Act; prescriptions for controlled dangerous substances; Physician Assistant Act; Committee; members; requirements; Public Health Code; authority for physician assistants to carry out certain functions; prescribing and administering controlled substances; supervision.
Controlled dangerous substances; authorizing certain disposal of substances in accordance with federal law; removing certain limitations. Effective date.
Practice of nursing; providing for independent prescriptive authority of Advanced Practice Registered Nurses who meet certain requirements; modifying various provisions of the Oklahoma Pharmacy Act, the Oklahoma Nursing Practice Act, and the Uniform Controlled Dangerous Substances Act; effective date.
Medical marijuana licenses; establishing certain requirements for license issuance; allowing certain actions by certain licensees; requiring certain information to be documented in certain inventory manifest prior to certain action. Effective date.
Medical marijuana licenses; establishing certain requirements for license issuance; allowing certain actions by certain licensees; requiring certain information to be documented in certain inventory manifest prior to certain action. Effective date.
Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.